Applied DNA Sciences, Inc.

APDN

US03815U4094

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
0.5958 ^USD	-1.52%		-70.06%	-95.17%

05-29	Applied DNA Sciences May Seek Potential Acquisitions	CI
05-28	US Equities Markets Close Mixed Tuesday as Nvidia Propels Nasdaq to Record High	MT

Applied DNA Sciences Appoints Elizabeth M Schmalz Ferguson to its Board

May 15, 2017 at 11:30 am

Applied DNA Sciences Inc. has appointed Elizabeth M Schmalz Ferguson to the board of directors of the company.

Latest news about Applied DNA Sciences, Inc.

Applied DNA Sciences May Seek Potential Acquisitions	05-29	CI
US Equities Markets Close Mixed Tuesday as Nvidia Propels Nasdaq to Record High	05-28	MT
Top Midday Decliners	05-28	MT
Applied DNA Sciences Prices $12 Million Public Offering of Units	05-28	MT
Maxim Downgrades Applied DNA Sciences to Hold From Buy	05-14	MT
Top Premarket Decliners	05-13	MT
Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q2 Revenue $929,631	05-10	MT
Applied DNA Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-10	CI
Applied DNA Sciences Regains Nasdaq Minimum Bid Price Requirement	05-10	MT
Banned Chinese cotton found in 19% of US retailers' merchandise, study shows	05-07	RE
Applied DNA Sciences, Inc. Receives Contract by HDT Bio for Rapid Vaccine Development Program	04-25	CI
Certain Warrants of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024.	04-02	CI
Certain Options of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024.	04-02	CI
Certain Common Stock of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024.	04-02	CI
Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress	03-14	CI
Applied DNA Sciences Files Prospectus for Potential Secondary Stock Offerings	03-12	MT
Transcript : Applied DNA Sciences, Inc., Q1 2024 Earnings Call, Feb 08, 2024	02-08
Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q1 Revenue $891,164	02-08	MT
Applied DNA Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-08	CI
Applied DNA Sciences, Inc. Announces Joint Development Agreement to Integrate Linea IVT Platform into CDMO Kudo Biotechnology?s mRNA Manufacturing Workflow	12-14	CI
HC Wainwright Cuts Price Target on Applied DNA Sciences to $2 From $4, Keeps Buy Rating	12-08	MT
Transcript : Applied DNA Sciences, Inc., Q4 2023 Earnings Call, Dec 07, 2023	12-07
Earnings Flash (APDN) APPLIED DNA SCIENCES Posts Q4 Revenue $779,736, vs. Street Est of $1.7M	12-07	MT
Applied DNA Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	12-07	CI
Applied DNA Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-07	CI

Chart Applied DNA Sciences, Inc.

Duration

Period

More charts

Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Companyâs proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Companyâs Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.

Sector

Medical Equipment, Supplies & Distribution

Calendar

11/06/2024 - Investor Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Applied DNA Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5958 USD

Average target price

30 USD

Spread / Average Target

+4,935.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
APPLIED DNA SCIENCES, INC.	-95.17%	6.09M
BIOMÉRIEUX	-3.43%	12.45B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.17%	8.22B
DIASORIN S.P.A.	+6.11%	5.72B
LANTHEUS HOLDINGS, INC.	+31.98%	5.67B
AUTOBIO DIAGNOSTICS CO., LTD.	-10.03%	4.11B
10X GENOMICS, INC.	-59.94%	2.68B
ANDON HEALTH CO., LTD.	+11.23%	2.68B
VITROLIFE AB	-5.14%	2.37B
MYRIAD GENETICS, INC.	+18.91%	2.06B

Diagnostic & Testing Substances

Applied DNA Sciences, Inc.

Equities

APDN

US03815U4094

Medical Equipment, Supplies & Distribution

Applied DNA Sciences Appoints Elizabeth M Schmalz Ferguson to its Board

EPS Revisions